Diferencia entre revisiones de «Alpha-2 agonists»
(Text replacement - "* " to "*") |
|||
| (No se muestran 2 ediciones intermedias de 2 usuarios) | |||
| Línea 1: | Línea 1: | ||
==Background== | ==Background== | ||
*Central | *Central α agonists lower blood pressure by stimulating α-receptors in the brain which causes peripheral vasodilation | ||
==Medications== | ==Medications== | ||
*[[clonidine]] | *[[clonidine]] | ||
*[[dexmedetomidine]] | |||
*[[guanabenz]] | *[[guanabenz]] | ||
*[[guanfacine]] | *[[guanfacine]] | ||
*[[methyldopa]] | *[[methyldopa]] | ||
*[[moxonidine]] | *[[moxonidine]] | ||
*[[Xylazine toxicity|Xylazine]] (veterinary med, drug of abuse) | |||
==Adverse effects== | ==Adverse effects== | ||
Revisión actual - 16:54 29 nov 2020
Background
- Central α agonists lower blood pressure by stimulating α-receptors in the brain which causes peripheral vasodilation
Medications
- clonidine
- dexmedetomidine
- guanabenz
- guanfacine
- methyldopa
- moxonidine
- Xylazine (veterinary med, drug of abuse)
Adverse effects
- sedation
- drying of the nasal mucosa
- rebound hypertension